Evidence map›Paper›PMID 32506626›Full record

ReviewPest management science2020

Isoflucypram, the first representative of a new succinate dehydrogenase inhibitor fungicide subclass: Its chemical discovery and unusual binding mode.

Philippe Desbordes, Bernd Essigmann, Stephanie Gary, Oliver Gutbrod, Michael Maue, Hans-Georg Schwarz

Erratum issuedAbstract readReview
In one paragraph

Review in Pest management science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Philippe DesbordesBayer SAS, Lyon, France.
Bernd EssigmannBayer SAS, Lyon, France.
Stephanie GaryBayer SAS, Lyon, France.
Oliver GutbrodBayer AG, Monheim am Rhein, Germany.
Michael MaueBayer AG, Monheim am Rhein, Germany.ORCID https://orcid.org/0000-0002-2447-5903
Hans-Georg SchwarzBayer AG, Monheim am Rhein, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Succinate dehydrogenase inhibitors (SDHIs) have played a crucial role in disease control to protect cereals as well as fruit and vegetables for more than a decade. Isoflucypram, the first representative of a newly installed subclass of SDHIs inside the Fungicide Resistance Action Committee (FRAC) family of complex II inhibitors, offers unparalleled long-lasting efficacy against major foliar diseases in cereals. Herein we report the chemical optimization from early discovery towards isoflucypram and the first hypothesis of its altered binding mode in the ubiquinone binding site of succinate dehydrogenase. © 2020 The Authors. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

Indexed as

Drug Resistance, FungalFungicides, IndustrialPlant DiseasesSuccinate DehydrogenaseSuccinic AcidFungicides, IndustrialSuccinate DehydrogenaseSuccinic AcidisoflucypramISYN-cyclopropyl-N-benzyl-pyrazole carboxamideSDHIubiquinone binding site

Identifiers

PMID32506626
PMCPMC7540001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.